Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 511,865 shares, a growth of ∞ from the July 30th total of 0 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 732,925 shares, the days-to-cover ratio is currently 0.7 days.
Insiders Place Their Bets
In related news, major shareholder Life Sciences Xi L.P. Frazier acquired 588,235 shares of Attovia Therapeutics stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the transaction, the insider directly owned 6,154,213 shares of the company's stock, valued at $104,621,621. This trade represents a 10.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Colin Walsh acquired 500,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the purchase, the director owned 3,020,632 shares in the company, valued at $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 2,740,587 shares of company stock worth $47,269,979. 0.99% of the stock is currently owned by insiders.
Institutional Trading of Attovia Therapeutics
A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO - Free Report) by 23.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,358 shares of the company's stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.'s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.
Attovia Therapeutics Stock Down 3.5%
ATTO stock opened at $20.70 on Friday. Attovia Therapeutics has a fifty-two week low of $16.15 and a fifty-two week high of $24.32.
About Attovia Therapeutics
(
Get Free Report)
Attovia Therapeutics, Inc NASDAQ: ATTO is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Attovia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Attovia Therapeutics wasn't on the list.
While Attovia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
